Edison Investment Research - CORIUM INTERNATIONAL (CORI) QuickView: Redefining the possibilities of drug patches

Report

Edison Investment Research

QuickView: Redefining the possibilities of drug patches

Corium is a specialty pharmaceutical company focused on the development of advanced transdermal drug delivery technology. The company receives revenue from three partnered products (including Crest Whitestrips) and is now developing products internally. It has two platforms (Corplex and MicroCor) that enable the formulation of poorly soluble drugs and biologics respectively, both of which were previously intractable. There is the potential for four 505(b)2 approvals in 2019-21.

19/05/2016 2 EN

Underlying

CORIUM INTERNATIONAL

Corium International is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products in transdermal and transmucosal delivery systems. The company has several proprietary programs focusing primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The company has developed and is the manufacturer of seven prescription drug and consumer products for its marketing partners. The company has two proprietary transdermal platforms: Corplex

See profile

US21887L1070 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

GlobeNewsWire

Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITYÂ® (donepezil transdermal system) for the Treatment of Alzheimerâ€™s Disease

Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITY® (donepezil transdermal system) for the Treatment of Alzheimer’s Disease MENLO PARK, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for patients and their families, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for ADLARITY (donepezil transdermal syst...

January 27, 2020 January 27, 2020 1 EN

GlobeNewsWire

Corium Appoints Perry Sternberg as Chief Executive Officer

Corium Appoints Perry Sternberg as Chief Executive Officer Former Shire Executive Brings Strong Track Record in Commercializing CNS Products MENLO PARK, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Corium, Inc. announced today that its Board of Directors has named Perry Sternberg as Chief Executive Officer. Mr. Sternberg is a senior pharmaceutical executive with commercial experience across a wide range of therapeutic areas in diverse markets. He most recently served a dual role at Shire Plc as the Head of U.S. Commercial for seven therapeutic area business units, as well as the Chief Co...

April 2, 2019 April 2, 2019 1 EN

GlobeNewsWire

Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares

Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex Donepezil MENLO PARK, Calif., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it has entered into a definitive merger ag...

October 11, 2018 October 11, 2018 1 EN

AGBA - A transformational deal

On 18 April, AGBA announced a surprise deal to acquire 100% of Triller Corp, a global AI-driven social video platform, in an all-stock transaction. Triller is privately-owned but has been independently valued at US$3.2bn. AGBA’s management is using a US$4bn valuation for the combined entity, in which AGBA shareholders will own 20% and Triller shareholders 80%. Triller recorded FY23 revenues of US$45m on 450m user accounts and 2.2m creators but is loss-making. In FY23, AGBA reported revenues of US$54m and 400,000+ clients. The combined group expects synergies from expanding and marketing to Tri...

8h / 31m 8h / 31m 1 EN

Sean Conroy

Sean Conroy

Biodexa Pharmaceuticals - In a period of transition

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into Q424, past the planned Phase IIa trial initiation for tolimidone. The next catalyst will likely be t...

12h / 40m 12h / 40m 1 EN

Toby Thorrington

Toby Thorrington

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

April 25, 2024 April 25, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Redefining the possibilities of drug patches

Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITYÂ® (donepezil transdermal system) for the Treatment of Alzheimerâ€™s Disease

Corium Appoints Perry Sternberg as Chief Executive Officer

Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares

AGBA - A transformational deal

Biodexa Pharmaceuticals - In a period of transition

Norcros - Sale of Johnson Tiles UK agreed

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe